Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$84.93 USD

84.93
2,385,980

+0.61 (0.72%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $85.09 +0.16 (0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Is First Trust Multi Cap Growth AlphaDEX ETF (FAD) a Strong ETF Right Now?

Smart Beta ETF report for FAD

Sheraz Mian headshot

Top Research Reports for Amazon, Tesla & UnitedHealth

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com (AMZN), Tesla (TSLA), and UnitedHealth Group (UNH).

Moderna (MRNA) Seeks Approval for COVID-19 Vaccine in Teens

Moderna (MRNA) is seeking authorization for conditional use of its COVID-19 vaccine, mRNA-1273, in adolescents in Europe and Canada.

Stock Market News for Jun 8, 2021

Benchmarks closed mixed on Monday as investors waited for more economic data to determine the course of economic recovery

Stock Market News for Jun 7, 2021

Benchmarks closed in the green on Friday as lesser-than-expected job additions eased concerns that the Federal Reserve might tighten monetary policies soon

Stock Market News for Jun 3, 2021

Wall Street closed marginally higher on Wednesday.

Biotech Stock Roundup: MRNA COVID-19 Vaccine Update, Drug Approvals for ALKS, MYOV & More

The biotech sector was in focus last week with pipeline and regulatory updates from Moderna (MRNA) and Alkermes (ALKS), among others.

Moderna (MRNA) Files for Full Approval of COVID-19 Vaccine

Moderna (MRNA) seeks full approval for its COVID-19 vaccine, mRNA-1273, in adults with initiation of rolling submission of a BLA. The company also boosts manufacturing capacity for the vaccine.

Benjamin Rains headshot

Find Strong Stocks with this First Profit Screener

The Zacks 'First Profit' screener is a solid place to start searching for strong stocks...

Baxter's (BAX) PrisMax 2 to Simplify Organ Support Therapies

Baxter's (BAX) PrisMax 2 aims to enhance user experience and help in addressing the unique demands of the ICU.

CureVac (CVAC) Announces Positive Data on COVID-19 Vaccine

CureVac (CVAC) announces the continuation of its COVID-19 vaccine study following the first interim analysis in 59 eligible COVID-19 cases.

Pfizer (PFE) COVID-19 Vaccine Gets Nod for Adolescents in EU

Pfizer (PFE)/BioNTech (BNTX) vaccine turns out to be 100% effective in preventing COVID-19 in adolescents aged 12-15 years old.

Sanofi/Glaxo Initiate Pivotal Global COVID-19 Vaccine Study

Sanofi (SNY) and Glaxo initiate phase III study to evaluate their adjuvanted COVID-19 vaccine candidate. A booster program will start soon.

Lumber Liquidators, Planet Fitness, Moderna, Pfizer and BioNTech highlighted as Zacks Bull and Bear of the Day

Lumber Liquidators, Planet Fitness, Moderna, Pfizer and BioNTech highlighted as Zacks Bull and Bear of the Day

Biotech Stock Roundup: MRNA's Vaccine Update & Pipeline Updates From REGN, BMY

The biotech sector was in focus last week with pipeline and regulatory updates from Moderna (MRNA) and Regeneron (REGN), among others.

Moderna's (MRNA) COVID-19 Vaccine 100% Effective in Teens

Moderna (MRNA) reports 100% efficacy of its COVID-19 vaccine in teenagers aged 12 to less than 18.

Pfizer (PFE) Tests COVID-19 Booster & Pneumococcal Vaccine Combo

Pfizer's (PFE) study is testing its pneumococcal vaccine candidate along with COVID-19 booster shot on 600 fully vaccinated adults 60 years and older.

AstraZeneca's (AZN) Coronavirus Vaccine Gets EUA in Japan

AstraZeneca's (AZN) COVID-19 vaccine Vaxzevria gets an approval for emergency use in Japan for active immunization of individuals aged 18 years and older.

Zacks Industry Outlook Highlights: Moderna, Amgen, BioNTech, Repligen Corp and Ovid Therapeutics

Zacks Industry Outlook Highlights: Moderna, Amgen, BioNTech, Repligen Corp and Ovid Therapeutics

Pfizer/BioNTech to Supply 1.8B More Doses of Comirnaty in EU

Pfizer (PFE)/BioNTech (BNTX) have a total supply order for 2.4 billion doses of its COVID-19 vaccine, Comirnaty in Europe.

BioNTech (BNTX) Up More Than 100% So Far This Year: Here's Why

BioNTech (BNTX) is riding high on the robust performance of its COVID-19 vaccine, BNT162b2, which has been developed in partnership with Pfizer.

Emergent (EBS) Issues Plan to Resume Bayview Facility Operation

Emergent (EBS) starts to make improvements at its Baview facility in order to meet FDA's standard and resume production of J&J's COVID-19 vaccine.

Pfizer (PFE) COVID-19 Vaccine for Adolescents Endorsed by CDC

Pfizer (PFE)/BioNTech (BNTX) vaccine was 100% effective in preventing COVID-19 in adolescents aged 12-15 years old.

The Zacks Analyst Blog Highlights: Regeneron, Moderna, Minerva Neurosciences, Amgen and Biogen

The Zacks Analyst Blog Highlights: Regeneron, Moderna, Minerva Neurosciences, Amgen and Biogen

Biotech Stock Roundup: REGN's Q1 Earnings Update, MRNA's Vaccine Data & More

The biotech sector was in focus last week with earnings updates from Regeneron (REGN) and Moderna (MRNA) and regulatory updates from Amgen, among others.